# Oncology Institute, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Oncology Institute, Inc.). ## Overview Oncology Institute, Inc. is a U.S.-based community oncology company that operates affiliated and managed outpatient cancer care clinics. Its network provides medical oncology, radiation oncology, infusion services, specialty pharmacy, and clinical trial support across multiple states through a mix of owned, affiliated, and contracted practices. ## Products & services • Medical oncology and hematology care • Radiation oncology services • Infusion therapy and outpatient cancer treatment • Specialty pharmacy dispensing • Clinical trial enrollment and support • Value-based care and delegated network management - **Patient services** (70%) — Outpatient oncology, hematology, infusion, and radiation care delivered through clinics and provider networks. - **Capitation and value-based contracts** (15%) — Population-based arrangements with payors and risk-bearing entities for managing oncology episodes of care. - **Specialty pharmacy** (10%) — Dispensing of oral and self-injectable oncology and supportive medications through office and mail order. - **Clinical trials and research support** (5%) — Participation in oncology, hematology, and supportive-care clinical research activities. - Medical oncology and hematology care - Radiation oncology services - Infusion therapy and outpatient cancer treatment - Specialty pharmacy dispensing - Clinical trial enrollment and support - Value-based care and delegated network management ## Customers TOI serves patients undergoing cancer treatment, but its economic customers are mainly payors and managed care organizations that contract for oncology care delivery and cost management. The company also serves Medicare, Medicare Advantage, Medi-Cal, commercial insurers, PBMs, and other risk-bearing entities through fee-for-service, capitation, and delegated arrangements. - **Payors and managed care organizations** (primary) — Contract for capitated, delegated, or shared-risk oncology care to control total episode cost and coordinate treatment. - **Medicare and Medicare Advantage patients** (primary) — Older oncology patients treated through clinic-based medical and radiation services under government reimbursement. - **Commercial insurance patients** (primary) — Employer and individual plan members receiving outpatient cancer care and infusion services. - **Medicaid / Medi-Cal patients** (secondary) — State-program patients treated in TOI markets where access and network adequacy matter. - **Clinical research participants and sponsors** (secondary) — Patients and third parties involved in oncology trials and related research activity. - Commercial insurers buying outpatient oncology access and cost control - Medicare and Medicare Advantage members receiving cancer treatment - Medi-Cal and other Medicaid patients in TOI clinic markets - Risk-bearing payors seeking delegated oncology management - Patients needing infusion, radiation, and specialty pharmacy support - Clinical research sponsors and partners using TOI trial infrastructure ## Geography TOI operates across 17 markets in five U.S. states, with clinic and network coverage centered in California, Florida, Arizona, Oregon, and Nevada. Its footprint is built market by market through a hybrid model of affiliated clinics, managed independent clinics, and contracted providers, which makes local payor relationships and network adequacy central to operations. - **California** (0%) — State-level operating footprint disclosed, but no revenue split provided. - **Florida** (0%) — State-level operating footprint disclosed, but no revenue split provided. - **Arizona** (0%) — State-level operating footprint disclosed, but no revenue split provided. - **Oregon** (0%) — State-level operating footprint disclosed, but no revenue split provided. - **Nevada** (0%) — State-level operating footprint disclosed, but no revenue split provided. - Operations span 17 markets across five U.S. states - Core states include California, Florida, Arizona, Oregon, and Nevada - Clinic network combines owned, affiliated, and contracted sites - Florida includes a managed provider network under the Florida Oncology Network brand - Local market density matters for payor contracts and network adequacy ## Strategy TOI’s strategy centers on expanding clinic capacity and market presence so it can support value-based oncology contracts and manage larger patient populations. It also seeks to broaden services through acquisitions, de novo clinics, specialty pharmacy, clinical trials, and deeper technology and operating integration. - **Build and acquire clinics in target markets** (short-term) — Clinic density supports payor contracts, patient access, and local market presence. - **Expand value-based care relationships** (medium-term) — Capitation and delegated arrangements are central to the company’s differentiated model. - **Broaden ancillary oncology services** (medium-term) — Additional services increase patient stickiness and deepen the care platform. - Expand clinic capacity to meet payor network adequacy requirements - Grow through acquisitions of aligned community oncology practices - Open de novo clinics in existing and new markets - Scale value-based and fully delegated oncology contracts - Add specialty pharmacy, trials, and ancillary services ## Risks TOI depends on building or acquiring clinics, winning payor contracts, and maintaining a reliable drug supply chain, so execution risk is tied directly to its operating model. It also faces reimbursement pressure, IT and cybersecurity exposure, goodwill impairment risk, and the usual clinical, regulatory, and labor risks of outpatient healthcare delivery. - **Clinic expansion and acquisition execution risk** [high] — The model requires new sites and practice integrations to support contracts and growth. - **Payor contracting and reimbursement pressure** [high] — Revenue depends on managed care, capitation, and fee-for-service terms. - **Single-source pharmaceutical supply disruption** [high] — A concentrated supplier base can interrupt drug availability and clinic operations. - **Information technology and cybersecurity incidents** [medium] — Clinical operations and billing rely on internal and third-party systems. - **Goodwill and intangible asset impairment** [medium] — Acquisitions create balance-sheet assets that must be tested for impairment. - Growth depends on opening or acquiring clinics on time and on budget - Payor contracts may be hard to win or renew on favorable terms - Single-source drug supply can disrupt treatment if interrupted - IT or cybersecurity failures could impair operations and data access - Goodwill and intangible assets may be impaired if performance weakens ## Accounting Revenue recognition is judgmental because TOI uses both capitation and fee-for-service arrangements, with variable consideration tied to encounters, credits, and reimbursement terms. Investors should also watch estimates around variable interest entities, deferred tax valuation allowances, and goodwill impairment, since acquisitions and clinic-level performance can materially affect reported results. - **Revenue recognition for capitation and fee-for-service** — Can shift quarterly revenue and margins - **Variable interest entities** — Affects reported revenue, expenses, assets, and liabilities - **Deferred tax valuation allowance** — Can materially affect tax expense and net assets - **Goodwill and intangible impairment testing** — Potential non-cash write-downs - Capitation and fee-for-service revenue require estimate-based recognition - Variable consideration can change with patient encounters and reimbursements - VIE consolidation affects which affiliated entities appear in results - Deferred tax assets depend on valuation allowance judgments - Goodwill is tested annually and can be impaired if clinic performance weakens --- *Last updated: 2026-04-29T04:43:49.891458+00:00*